Clinical Trial Detail

NCT ID NCT02230306
Title Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Hussein Tawbi
Indications

melanoma

Therapies

Cobimetinib + Vemurafenib

Age Groups: adult

Additional content available in CKB BOOST